$TWST

Cho Dennis sold $1.3M of TWST

Cho Dennis (See Remarks) sold 14,205 shares of Twist Bioscience Corp (TWST) at $89.75 ($1.27M total) on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cho Dennis
Published Jun 26, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
high confidence
Mentioned
$TWST
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The only new information is the specific sale size, price, and post-transaction holdings under a 10b5-1 plan; it does not include any new company performance, guidance, or regulatory developments.

02

Market read

Traders may note the insider selling activity, but the 10b5-1 structure and lack of fundamental updates make it low-conviction for directional trading.

03

What to watch

The article does not state whether other insiders sold/bought around the same window, nor does it provide context on total planned volume or remaining plan size.

Relevance 5/10Novelty 3/10Timing: filed June 26, covering a June 24 sale

Background

The article is a SEC Form 4 insider transaction disclosure for Twist Bioscience, reported via SEC EDGAR.

Company-level read

Ticker impact

$TWSTNeutralHigh confidence
Context

Twist Bioscience insider Dennis Cho filed a Form 4 open-market sale of 14,205 shares at $89.75 on June 24 under a 10b5-1 plan.

Expected impact

Likely minimal price impact; any effect is short-lived and sentiment-driven rather than fundamental.

Evidence & confidence

The filing is an open-market sale under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change disclosed in the text.

Market effects

No clear sector read-through from a single routine insider sale disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is on a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations, so traders may discount it.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider transaction disclosure.

  • Dennis Cho

    Officer who executed the open-market sale under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.